Filing Details
- Accession Number:
- 0001209191-17-050294
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-08-25 17:17:05
- Reporting Period:
- 2017-08-24
- Accepted Time:
- 2017-08-25 16:17:05
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1628738 | Audentes Therapeutics Inc. | BOLD | Biological Products, (No Disgnostic Substances) (2836) | 461606174 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1679132 | Mary Newman | C/O Audentes Therapeutics, Inc. 600 California Street, 17Th Floor San Francisco CA 94108 | Svp, Regulatory Affairs | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-08-24 | 10,000 | $2.19 | 10,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-08-24 | 10,000 | $20.00 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2017-08-24 | 10,000 | $0.00 | 10,000 | $2.19 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
43,817 | 2025-02-04 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- The option vested as to 25% of the total shares on October 1, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on October 1, 2018, subject to the reporting person's provision of service to the issuer on each vesting date.